Much of our knowledge of the protein PD-1, a leading cancer treatment target, comes from studies in mice. In a comprehensive assessment of PD-1, researchers have found that PD-1 in mice is ...

Programmed cell death protein 1,” or PD-1, has been considered a key target in cancer therapies since its discovery in the ...

Cancer immunotherapy drugs called immune checkpoint inhibitors take the brakes off the body’s immune system, allowing it to ...

Evaxion Biotech has completed subject dosing in the Phase II trial of its personalised peptide-based cancer vaccine, EVX-01, ...

Researchers have discovered that mouse PD-1 is significantly weaker than human PD-1, calling into question their reliability ...

About LM-299 LM-299 is an investigational bispecific antibody targeting both programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF). This innovative therapeutic ...

This executive interview, sponsored by BeiGene, is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene.